Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10373554 | 0.79 | NPSR1 (0.33) | NPSR1ALDH1A1HPGD | |
| SCHEMBL18998188 | 0.76 | PDE10A (0.33) | — | |
| SCHEMBL4558725 | 0.73 | GABRA1 (0.34) | NPSR1 | |
| SCHEMBL3856071 | 0.72 | NPSR1 (0.30) | NPSR1 | |
| SCHEMBL20034210 | 0.70 | — | — | |
| SCHEMBL10385703 | 0.70 | BCHE (0.35) | — | |
| SCHEMBL10144470 | 0.69 | PDE10A (0.43) | — | |
| SCHEMBL10835168 | 0.69 | PDE10A (0.43) | — | |
| SCHEMBL27923489 | 0.69 | — | — | |
| SCHEMBL9116271 | 0.67 | NPSR1 (0.39) | NPSR1ALDH1A1HPGDL3MBTL1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891364-B2 | Methods of selectively forming substituted pyrazines | R.J. REYNOLDS TOBACCO COMPANY (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117486811-A | Method for selectively forming substituted pyrazines | R.J.雷诺兹烟草公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-110637012-B | Method for selectively forming substituted pyrazines | R.J.雷诺兹烟草公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20210403437-A1 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES | REYNOLDS TOBACCO CO R (US) | 2021-12-30 | — | — | US | disclosed |
| US-11091446-B2 | Methods of selectively forming substituted pyrazines | R.J. REYNOLDS TOBACCO COMPANY (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3601238-A1 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES | R. J. Reynolds Tobacco Company (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110637012-A | Process for selectively forming substituted pyrazines | R.J.雷诺兹烟草公司 | 2019-12-31 | — | — | CN | disclosed |
| WO-2018172995-A1 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES | R. J. REYNOLDS TOBACCO COMPANY (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20180273492-A1 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES | R.J. REYNOLDS TOBACCO COMPANY | 2018-09-27 | — | — | US | disclosed |
| CN-101268064-A | Pyrazine derivatives useful as adenosine receptor antagonists | ALMIRALL LAB (ES) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273492-A1 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES | KHK, HK2, HK1 | NPSR1 1842/4885ALDH1A1 542/4885HPGD 36/4885 |
| US-11891364-B2 | Methods of selectively forming substituted pyrazines | KHK, HK2, HK1 | NPSR1 1842/4885ALDH1A1 542/4885HPGD 36/4885 |
| US-11091446-B2 | Methods of selectively forming substituted pyrazines | KHK, HK2, HK1 | NPSR1 1842/4885ALDH1A1 542/4885HPGD 36/4885 |
| US-20210403437-A1 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES | KHK, HK2, HK1 | NPSR1 1842/4885ALDH1A1 542/4885HPGD 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.